Frontiers in endocrinology · 2026
Mortality trends in the co-occurrence of urinary tract cancer and diabetes mellitus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ou Chen-Zhang, Xiong Yu-Jun, Meng Xiang-Da, Lv Tian, Song Lide
Аннотация
BACKGROUND: Urinary tract cancers and diabetes mellitus often co-occur and may interact to worsen clinical outcomes, yet long-term mortality patterns in this population remain poorly understood.
METHODS: Using national death certificate data from 1999 to 2024, we identified adults aged ≥25 years with both urinary tract cancers (ICD-10: C64-C68) and diabetes mellitus (ICD-10: E10-E14). Age-adjusted mortality rates (AAMRs) were standardized to the 2000 U.S. population. Temporal trends were assessed via Joinpoint regression to estimate annual percent changes (APC) and average annual percent changes (AAPC). Analyses were stratified by age, sex, race, region, and urbanization level.
RESULTS: Deaths increased from 1, 566 in 1999 to 4, 487 in 2024; the AAMR rose from 0.87 to 1.53 per 100, 000 (AAPC 2.30%; 95% CI: 1.32%-3.29%). Mortality surged during 2018-2021 (APC 9.93%) before leveling off. Men had higher rates and a steeper rise than women (AAPC 2.42% vs. 1.00%). The oldest age group (≥85 years) showed the largest increase (AAPC 3.61%). Geographically, the South outpaced other regions (AAPC 3.57%), and nonmetropolitan areas exceeded metropolitan ones in both mortality level and growth (AAPC 3.19% vs. 1.85%). Among racial groups, non-Hispanic White individuals experienced the greatest rise (AAPC 2.51%).
CONCLUSIONS: Over two decades, mortality from coexisting urinary tract cancers and diabetes rose substantially, with marked demographic and geographic disparities. Integrated prevention and management strategies are urgently needed.
METHODS: Using national death certificate data from 1999 to 2024, we identified adults aged ≥25 years with both urinary tract cancers (ICD-10: C64-C68) and diabetes mellitus (ICD-10: E10-E14). Age-adjusted mortality rates (AAMRs) were standardized to the 2000 U.S. population. Temporal trends were assessed via Joinpoint regression to estimate annual percent changes (APC) and average annual percent changes (AAPC). Analyses were stratified by age, sex, race, region, and urbanization level.
RESULTS: Deaths increased from 1, 566 in 1999 to 4, 487 in 2024; the AAMR rose from 0.87 to 1.53 per 100, 000 (AAPC 2.30%; 95% CI: 1.32%-3.29%). Mortality surged during 2018-2021 (APC 9.93%) before leveling off. Men had higher rates and a steeper rise than women (AAPC 2.42% vs. 1.00%). The oldest age group (≥85 years) showed the largest increase (AAPC 3.61%). Geographically, the South outpaced other regions (AAPC 3.57%), and nonmetropolitan areas exceeded metropolitan ones in both mortality level and growth (AAPC 3.19% vs. 1.85%). Among racial groups, non-Hispanic White individuals experienced the greatest rise (AAPC 2.51%).
CONCLUSIONS: Over two decades, mortality from coexisting urinary tract cancers and diabetes rose substantially, with marked demographic and geographic disparities. Integrated prevention and management strategies are urgently needed.